Trends in cancer survival in 11 European populations from 1990 to 2009: A model-based analysis

Annals of Oncology

Volumn 20, Issue 3, 2009, Pages 564-573

  Gondos, A ^a   Bray, Freddie ^b   Hakulinen, T ^c   Brenner, H ^a   Aareleid, Tiiu ^d   Willem, Jan ^e   Coebergh, Jan Willem ^f   Crocetti, Emanuele ^g   Gondos, Adam ^a   Hakulinen, Timo ^c   Holleczek, Bernd ^h   Janssen Heijnen, Maryska ^f   Kurtinaitis, Juozas ⁱ   Mägi, Margit ^j   Rachtan, Jadwiga ^k   Rosso, Stefano ^l   Usel, Massimo ^m   Žakelj, Maja Primic ⁿ  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b CANCER REGISTRY OF NORWAY   (Norway)

^c FINNISH CANCER REGISTRY   (Finland)

^d NATIONAL INSTITUTE FOR HEALTH DEVELOPMENT   (Estonia)

^e Scottish Cancer Registry   (United Kingdom)

^f Eindhoven Cancer Registry   (Netherlands)

^g Florence Cancer Registry   (Italy)

^h Saarland Cancer Registry   (Germany)

ⁱ Cancer Registry of Lithuania   (Lithuania)

^j Cancer Registry of Estonia   (Estonia)

^k Cracow Cancer Registry   (Poland)

^l Cancer Research Centre Torino   (Italy)

^m GENEVA CANCER REGISTRY   (Switzerland)

ⁿ INSTITUTE OF ONCOLOGY   (Slovenia)

more..

Author keywords

Cancer registries; Neoplasms; Survival

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER REGISTRY; CANCER SURVIVAL; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; EARLY DIAGNOSIS; EUROPE; FEMALE GENITAL TRACT CANCER; GEOGRAPHIC DISTRIBUTION; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CANCER; NONHODGKIN LYMPHOMA; OVARY CANCER; PERIODICITY; PRIORITY JOURNAL; PROSTATE CANCER; STOMACH CANCER; SURVIVAL TIME; THYROID CANCER; TREND STUDY; URINARY TRACT CANCER; UTERUS CANCER;

EID: 61649125819     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn639     Document Type: Article

References (52)

1. Brenner H, Hakulinen T. Up-to-date estimates of cancer patient survival even with common latency in cancer registration. Cancer Epidemiol Biomarkers Prev 2006; 15: 1727-1732.
2. Gondos A, Bray F, Brewster DH et al. Recent trends in cancer survival across Europe between 2000 and 2004: A model-based period analysis from 12 cancer registries. Eur J Cancer 2008; 44: 1463-1475.
3. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: A statistical methodology. Natl Cancer Inst Monogr 1961; 6: 101-121.
4. Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Methodological Note No. 10. End Results Section. Bethesda, MD: National Cancer Institute 1959.
5. Brenner H, Gefeller O, Hakulinen T. Period analysis for 'up-to-date' cancer survival data: Theory, empirical evaluation, computational realisation and applications. Eur J Cancer 2004; 40: 326-335.
6. Brenner H, Hakulinen T. Up-to-date long-term survival curves of patients with cancer by period analysis. J Clin Oncol 2002; 20: 826-832.
7. Brenner H, Soderman B, Hakulinen T. Use of period analysis for providing more up-to-date estimates of long-term survival rates: Empirical evaluation among 370,000 cancer patients in Finland. Int J Epidemiol 2002; 31: 456-462.
8. Talbäck M, Stenbeck M, Rosen M. Up-to-date long-term survival of cancer patients: An evaluation of period analysis on Swedish Cancer Registry data. Eur J Cancer 2004; 40: 1361-1372.
9. Brenner H, Rachet B. Hybrid analysis for up-to-date long-term survival rates in cancer registries with delayed recording of incident cases. Eur J Cancer 2004; 40: 2494-2501.
10. Brenner H, Hakulinen T. Model based hybrid analysis of cancer patient survival. Eur J Cancer 2007; 43: 921-927.
11. Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 2004; 40: 2307-2316.
12. SAS 9.1. Cary, NC: SAS Institute Inc. 2006.
13. Berrino F, De Angelis R, Sant M et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007; 8: 773-783.
14. Coleman MP, Gatta G, Verdecchia A et al. EUROCARE-3 summary: Cancer survival in Europe at the end of the 20th century. Ann Oncol 2003; 14 (Suppl 5): V128-v149.
15. Sant M, Capocaccia R, Coleman MP et al. Cancer survival increases in Europe, but international differences remain wide. Eur J Cancer 2001; 37: 1659-1667.
16. Verdecchia A, Francisci S, Brenner H et al. Recent cancer survival in Europe: A 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007; 8: 784-796.
17. Sant M, Aareleid T,Berrino F et al. EUROCARE-3: Survival of cancer patients diagnosed 1990-94 - results and commentary. Ann Oncol 2003; 14 (Suppl 5): V61-v118.
18. Berrino F, Micheli A, Sant M, Capocaccia R. Interpreting survival differences and trends. Tumori 1997; 83: 9-16.
19. Dickman PW, Adami HO. Interpreting trends in cancer patient survival. J Intern Med 2006; 260: 103-117.
20. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA 2000; 283: 2975-2978.
21. Draisma G, Boer R, Otto SJ et al. Lead times and overdetection due to prostat-especific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868-878.
22. Etzioni R, Penson DF, Legler JM et al. Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002; 94: 981-990.
23. D'Ambrosio G, Samani F, Cancian M, De Mola C. Practice of opportunistic prostate-specific antigen screening in Italy: Data from the Health Search database. Eur J Cancer Prev 2004; 13: 383-386.
24. Gavin A, McCarron P, Middleton RJ et al. Evidence of prostate cancer screening in a UK region. BJU Int 2004; 93: 730-734.
25. Lim L, Michael M, Mann GB, Leong T. Adjuvant therapy in gastric cancer. J Clin Oncol 2005; 23: 6220-6232.
26. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
27. Ragnhammar P, Hafstrom L, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 2001; 40: 282-308.
28. Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ. Adjuvant treatment of colorectal cancer. CA Cancer J Clin 2007; 57: 168-185.
29. Martling A, Holm T, Rutqvist LE et al. Impact of a surgical training programme on rectal cancer outcomes in Stockholm. Br J Surg 2005; 92: 225-229.
30. Martling AL, Holm T, Rutqvist LE et al. Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet 2000; 356: 93-96.
31. Quirke P. Training and quality assurance for rectal cancer: 20 years of data is enough. Lancet Oncol 2003; 4: 695-702.
32. Tamoxifen for early breast cancer. Cochrane Database Syst Rev 2001; CD000486.
33. Colozza M, de Azambuja E, Cardoso F et al. Breast cancer: Achievements in adjuvant systemic therapies in the pre-genomic era. Oncologist 2006; 11: 111-125.
34. Goldhirsch A, Wood WC, Senn HJ et al. Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1995; 87: 1441-1445.
35. Hind D, Ward S, De Nigris E et al. Hormonal therapies for early breast cancer: Systematic review and economic evaluation. Health Technol Assess 2007; 11: Iii-iv, ix-xi 1-134.
36. Senn HJ, Thurlimann B, Goldhirsch A et al. Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer. Breast 2003; 12: 569-582.
37. Trimbos JB, Vergote I, Bolis G et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 2003; 95: 113-125.
38. Vernooij F, Heintz P, Witteveen E, van der Graaf Y. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: A systematic review. Gynecol Oncol 2007; 105: 801-812.
39. Mike S, Harrison C, Coles B et al. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev 2006; CD005247.
40. Peschel RE, Colberg JW. Surgery, brachytherapy. external-beam radiotherapy for early prostate cancer. Lancet Oncol 2003; 4: 233-241.
41. Etzioni R, Tsodikov A, Mariotto A et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control 2008; 19: 175-181.
42. Mink SA, Armitage JO. High-dose therapy in lymphomas: A review of the current status of allogeneic and autologous stem cell transplantation in Hodgkin's disease and non-Hodgkin's lymphoma. Oncologist 2001; 6: 247-256.
43. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003; 14: 520-535.
44. Quintas-Cardama A, Cortes JE. Chronic myeloid leukemia: Diagnosis and treatment. Mayo Clin Proc 2006; 81: 973-988.
45. Ravandi F, Burnett AK, Agura ED, Kantarjian HM. Progress in the treatment of acute myeloid leukemia. Cancer 2007; 110: 1900-1910.
46. Wibe A, Moller B, Norstein J et al. A national strategic change in treatment policy for rectal cancer-implementation of total mesorectal excision as routine treatment in Norway. A national audit. Dis Colon Rectum 2002; 45: 857-866.
47. Baxter NN, Virnig DJ, Rothenberger DA et al. Lymph node evaluation in colorectal cancer patients: A population-based study. J Natl Cancer Inst 2005; 97: 219-225.
48. Perry N, Broeders M, de Wolf C et al. European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition-summary document. Ann Oncol 2008.
49. MacKie RM, Bray CA, Hole DJ et al. Incidence of and survival from malignant melanoma in Scotland: An epidemiological study. Lancet 2002; 360: 587-591.
50. Weinstock MA. Progress and prospects on melanoma: The way forward for early detection and reduced mortality. Clin Cancer Res 2006; 12: 2297s-2300s.
51. Du Bois A, Rochon J, Lamparter C, Pfisterer J. Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int J Gynecol Cancer 2005; 15: 183-191.
52. Vernooij F, Heintz AP, Witteveen PO et al. Specialized care and survival of ovarian cancer patients in The Netherlands: Nationwide cohort study. J Natl Cancer Inst 2008; 100: 399-406.